Anatara Lifesciences Ltd

Anatara Lifesciences (ASX: ANR) has reported that recruitment for Stage 2 of its pivotal GaRP (Gastrointestinal ReProgramming) trial for the treatment of irritable bowel syndrome (IBS) is proceeding well and remains on budget. The company has also confirmed an extension to the recruitment timeline through to August. Stage 2 of the GaRP trial follows the […]

Recruitment is advancing for Stage 2 of Anatara Lifesciences’ (ASX: ANR) pivotal gastrointestinal reprogramming (GaRP) trial to treat irritable bowel syndrome (IBS). The five trial sites in Melbourne, Sydney and Brisbane have received more than 500 expressions of interest and have completed the standard screening processes consistent with Stage 1. Thirteen participants have been enrolled […]

Anatara Lifesciences (ASX: ANR) has initiated Stage 2 of a Phase II gastrointestinal re-programming (GaRP) trial to treat patients with irritable bowel syndrome (IBS). The milestone follows “highly encouraging” findings from Stage 1 of the trial, whereby 61 intent-to-treat participants were given low- and high-dose regimens of the medication. Stage 1 of the trial was […]

Investors are scrambling around looking for a new investment thesis after the long-awaited prospect of global official interest rate cuts continued to fade out of view. A combination of stubbornly resurgent inflation in the United States, the potentially worsening war in the Middle East and the prospect of a US election campaign all contributed to […]